OPKO Health, Inc.

DB:XCY Stock Report

Market Cap: €1.0b

OPKO Health Valuation

Is XCY undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

2/6

Valuation Score 2/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Sales vs Peers

  • Price-To-Sales vs Industry

  • Price-To-Sales vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of XCY when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: XCY (€1.46) is trading below our estimate of fair value (€10.52)

Significantly Below Fair Value: XCY is trading below fair value by more than 20%.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for XCY?

Key metric: As XCY is unprofitable we use its Price-To-Sales Ratio for relative valuation analysis.

The above table shows the Price to Sales ratio for XCY. This is calculated by dividing XCY's market cap by their current revenue.
What is XCY's PS Ratio?
PS Ratio1.5x
SalesUS$711.41m
Market CapUS$1.08b

Price to Sales Ratio vs Peers

How does XCY's PS Ratio compare to its peers?

The above table shows the PS ratio for XCY vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PSEstimated GrowthMarket Cap
Peer Average0.8x
SYAB SYNLAB
1x4.4%€2.5b
FRE Fresenius SE KGaA
0.8x3.6%€18.8b
FME Fresenius Medical Care
0.7x3.8%€12.6b
V3V VITA 34
0.9x2.9%€72.5m
XCY OPKO Health
1.5x6.8%€1.1b

Price-To-Sales vs Peers: XCY is expensive based on its Price-To-Sales Ratio (1.5x) compared to the peer average (0.8x).

Price to Sales Ratio vs Industry

How does XCY's PS Ratio compare vs other companies in the DE Healthcare Industry?

2 CompaniesPrice / SalesEstimated GrowthMarket Cap
EIF MedNation
0.1xn/aUS$5.23m
TLIK Arzneiwerk VIDA
0.08xn/aUS$4.80m
No more companies available in this PS range
XCY 1.5xIndustry Avg. 0.6xNo. of Companies4PS00.40.81.21.62+
2 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Sales vs Industry: XCY is expensive based on its Price-To-Sales Ratio (1.5x) compared to the European Healthcare industry average (0.6x).

Price to Sales Ratio vs Fair Ratio

What is XCY's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

XCY PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio1.5x
Fair PS Ration/a

Price-To-Sales vs Fair Ratio: Insufficient data to calculate XCY's Price-To-Sales Fair Ratio for valuation analysis.

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst XCY forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
Current€1.46
€3.75
+157.2%
56.8%€8.05€1.89n/a6
Nov ’25n/a
€3.63
0%
56.8%€7.79€1.83n/a6
Oct ’25€1.32
€3.63
+174.6%
56.8%€7.79€1.83n/a6
Sep ’25€1.46
€3.63
+148.0%
56.8%€7.79€1.83n/a6
Aug ’25n/a
€3.53
0%
61.5%€7.83€1.38n/a6
Jul ’25€1.10
€3.96
+260.0%
53.8%€7.91€1.40n/a6
Jun ’25n/a
€3.96
0%
53.8%€7.91€1.40n/a6
May ’25n/a
€3.96
0%
53.8%€7.91€1.40n/a6
Apr ’25€1.06
€3.96
+272.4%
53.8%€7.91€1.40n/a6
Mar ’25€0.86
€3.92
+353.7%
53.8%€7.84€1.38n/a6
Feb ’25n/a
€3.96
0%
50.6%€7.77€1.83n/a6
Jan ’25n/a
€4.13
0%
48.2%€7.95€1.87n/a6
Dec ’24n/a
€4.13
0%
48.2%€7.95€1.87n/a6
Nov ’24n/a
€4.07
0%
48.0%€7.72€1.82n/a6
Oct ’24€1.45
€4.07
+180.2%
48.0%€7.72€1.82€1.326
Sep ’24€1.65
€4.07
+147.5%
48.0%€7.72€1.82€1.466
Aug ’24n/a
€3.97
0%
49.7%€7.82€1.84n/a6
Jul ’24€1.94
€3.97
+104.8%
49.7%€7.82€1.84€1.106
Jun ’24€1.24
€4.34
+250.8%
43.0%€7.71€2.72n/a5
May ’24n/a
€4.58
0%
43.0%€8.03€2.84n/a5
Apr ’24n/a
€4.58
0%
43.0%€8.03€2.84€1.065
Mar ’24n/a
€4.58
0%
43.0%€8.03€2.84€0.865
Feb ’24n/a
€4.66
0%
40.5%€8.00€2.82n/a5
Jan ’24n/a
€4.66
0%
40.5%€8.00€2.82n/a5
Dec ’23n/a
€5.43
0%
36.0%€8.49€3.50n/a4
Nov ’23n/a
€5.57
0%
30.7%€8.33€3.92n/a4

Analyst Forecast: Target price is more than 20% higher than the current share price, but analysts are not within a statistically confident range of agreement.

Discover undervalued companies

LNA Santé

€244.9m

Engages in the management and operation of health establishments.

2N3

€23.30

7D

-5.3%

1Y

19.1%

Shandong Weigao Group Medical Polymer

HK$19.8b

Engages in the research and development, production, wholesale, and sale of medical devices in the People’s Republic of China.

UK2

HK$0.51

7D

-10.5%

1Y

-38.6%

Top Glove Corporation Bhd

RM 7.8b

An investment holding company, manufactures, trades in, and sells gloves in Malaysia, Thailand, the People’s Republic of China, and internationally.

5OU

RM 0.98

7D

0.5%

1Y

-82.5%